| Literature DB >> 30323832 |
Guojun Liu1, Zihao Chen2, Irina G Danilova1, Mikhail A Bolkov3, Irina A Tuzankina3, Guoqing Liu4.
Abstract
Basal and luminal subtypes of muscle-invasive bladder cancer (MIBC) have distinct molecular profiles and heterogeneous clinical behaviors. The interactions between mRNAs and lncRNAs, which might be regulated by miRNAs, have crucial roles in many cancers. However, the miRNA-dependent crosstalk between lncRNA and mRNA in specific MIBC subtypes still remains unclear. In this study, we first classified MIBC into two conservative subtypes using miRNA, mRNA and lncRNA expression data derived from The Cancer Genome Atlas. Then we investigated subtype-related biological pathways and evaluated the subtype classification performance using Decision Trees, Random Forest and eXtreme Gradient Boosting (XGBoost). At last, we explored potential miRNA-mediated lncRNA-mRNA crosstalks based on co-expression analysis. Our results show that: (1) the luminal subtype is primarily characterized by upregulation of metabolism-related pathways while the basal subtype is predominantly characterized by upregulation of epithelial-mesenchymal transition, metastasis, and immune system process-related pathways; (2) the XGBoost prediction model is consistently robust for classification of the molecular subtypes of MIBC across four datasets (The area under the ROC curve > 0.9); (3) the expression levels of the molecules in the miR-200c and miR141-mediated lncRNA-mRNA crosstalks differ considerably between the two subtypes and have close relationships with the prognosis of MIBC. The miR-200c and miR-141-dependent mRNA-lncRNA crosstalks might be of great significance in tumorigenesis and tumor progression and may serve as the novel prognostic predictors and classification markers of MIBC subtypes.Entities:
Keywords: XGBoost; miR-141; miR200c; muscle-invasive bladder cancer; random forest; subtypes
Year: 2018 PMID: 30323832 PMCID: PMC6172409 DOI: 10.3389/fgene.2018.00422
Source DB: PubMed Journal: Front Genet ISSN: 1664-8021 Impact factor: 4.599
Top-ranked terms of GO-BP, KEGG and Hallmark gene sets for the luminal subtype.
| Gene set name | Size | NES | FDR |
|---|---|---|---|
| GO monocarboxylic acid catabolic process | 95 | 2.5151 | 0 |
| GO oxidative phosphorylation | 73 | 2.4333 | 0 |
| GO fatty acid catabolic process | 80 | 2.4284 | 0 |
| GO fatty acid beta oxidation | 51 | 2.3211 | 0 |
| GO electron transport chain | 78 | 2.3116 | 0 |
| GO organic acid catabolic process | 92 | 2.2781 | 2.26E-04 |
| GO mitochondrial respiratory chain complex assembly | 42 | 2.1788 | 0.0014 |
| GO lipid oxidation | 63 | 2.1586 | 0.0015 |
| GO mitochondrial respiratory chain complex i biogenesis | 199 | 2.1449 | 0.0018 |
| GO establishment of protein localization to endoplasmic reticulum | 70 | 2.1285 | 0.0022 |
| KEGG ribosome | 87 | 2.3289 | 0 |
| KEGG alpha linolenic acid metabolism | 19 | 2.0770 | 5.29E-04 |
| KEGG metabolism of xenobiotics by cytochrome p450 | 68 | 2.0424 | 5.36E-04 |
| KEGG valine leucine and isoleucine degradation | 44 | 1.9767 | 0.00137 |
| KEGG drug metabolism cytochrome p450 | 70 | 1.9727 | 0.00120 |
| KEGG oxidative phosphorylation | 116 | 1.9372 | 0.00209 |
| KEGG peroxisome | 78 | 1.9320 | 0.00214 |
| KEGG fatty acid metabolism | 42 | 1.9184 | 0.00229 |
| KEGG retinol metabolism | 63 | 1.8697 | 0.00391 |
| KEGG linoleic acid metabolism | 29 | 1.8393 | 0.00482 |
| Hallmark oxidative phosphorylation | 198 | 1.5145 | 0.05830 |
| Hallmark bile acid metabolism | 112 | 1.4110 | 0.07668 |
| Hallmark peroxisome | 103 | 1.4095 | 0.05174 |
| Hallmark adipogenesis | 191 | 1.3794 | 0.05125 |
| Hallmark fatty acid metabolism | 156 | 1.2596 | 0.11892 |
Top-ranked categories of GO-BP, KEGG and Hallmark gene sets for the basal subtype.
| Gene set name | Size | NES | FDR |
|---|---|---|---|
| GO extracellular structure organization | 297 | –2.8256 | 0 |
| GO antigen processing and presentation of exogenous peptide antigen via mhc class i | 65 | –2.7258 | 0 |
| GO antigen processing and presentation | 206 | –2.6334 | 0 |
| GO antigen processing and presentation of peptide antigen | 170 | –2.6246 | 0 |
| GO antigen processing and presentation of peptide antigen via mhc class i | 90 | –2.6134 | 0 |
| GO chondroitin sulfate biosynthetic process | 25 | –2.6008 | 0 |
| GO collagen fibril organization | 36 | –2.5958 | 0 |
| GO regulation of innate immune response | 349 | –2.5825 | 0 |
| GO positive regulation of defense response | 360 | –2.5802 | 0 |
| GO cytokine mediated signaling pathway | 440 | –2.5675 | 0 |
| KEGG focal adhesion | 197 | –2.6862 | 0 |
| KEGG cytokine cytokine receptor interaction | 257 | –2.5127 | 0 |
| KEGG ecm receptor interaction | 84 | –2.512 | 0 |
| KEGG proteasome | 43 | –2.4802 | 0 |
| KEGG leishmania infection | 69 | –2.4718 | 0 |
| KEGG viral myocarditis | 68 | –2.4178 | 0 |
| KEGG hematopoietic cell lineage | 85 | –2.4134 | 0 |
| KEGG regulation of actin cytoskeleton | 211 | –2.3911 | 0 |
| KEGG allograft rejection | 35 | –2.3902 | 0 |
| KEGG autoimmune thyroid disease | 50 | –2.3778 | 0 |
| Hallmark epithelial-mesenchymal transition | 197 | –3.2473 | 0 |
| Hallmark inflammatory response | 197 | –3.0190 | 0 |
| Hallmark interferon gamma response | 197 | –2.9964 | 0 |
| Hallmark interferon alpha response | 94 | –2.9491 | 0 |
| Hallmark allograft rejection | 199 | –2.9010 | 0 |
| Hallmark G2M checkpoint | 194 | –2.6389 | 0 |
| Hallmark E2F targets | 196 | –2.6177 | 0 |
| Hallmark TNF-a signaling via NF-kB | 198 | –2.5512 | 0 |
| Hallmark complement | 195 | –2.5475 | 0 |
| Hallmark mTORC1 signaling | 198 | –2.441 | 0 |